Johnson & Johnson (NYSE:JNJ) Stock Sale Reported by Rep. Thomas H. Kean, Jr.

Key Points

• Rep. Thomas H. Kean Jr. sold $1,001–$15,000 of Johnson & Johnson shares on September 30, following another JNJ sale in August. He has also recently sold shares of several healthcare and technology companies while purchasing ESAB, Texas Instruments and MasTec.
• Johnson & Johnson reported quarterly EPS of $2.59, exceeding estimates, while revenue rose 5.9% year over year to $25.40 billion. The company reaffirmed 2026 adjusted EPS guidance of $11.05–$11.15 and declared a quarterly dividend of $1.34, yielding about 2.0% annually.
• JNJ shares opened at $270.81, near their 52-week high of $282.02, and analysts maintain a “Moderate Buy” consensus with an average price target of $275.92. Positive Impella heart-device data support the MedTech outlook, though some coverage suggests the stock may already be fully valued after strong recent gains.

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson NYSE: JNJ. In a filing disclosed on October 30th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on September 30th. The trade occurred in the Representative's "STATE STREET BANK & TRUST CO." account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Stryker NYSE: SYK on 9/30/2026.
• Purchased $1,001 - $15,000 in shares of ESAB NYSE: ESAB on 9/29/2026.
• Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 9/23/2026.
• Sold $1,001 - $15,000 in shares of Abbott Laboratories NYSE: ABT on 9/17/2026.
• Purchased $1,001 - $15,000 in shares of Texas Instruments NASDAQ: TXN on 9/17/2026.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/27/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/27/2026.
• Sold $1,001 - $15,000 in shares of Johnson & Johnson NYSE: JNJ on 8/27/2026.
• Purchased $1,001 - $15,000 in shares of MasTec NYSE: MTZ on 8/21/2026.
• Sold $1,001 - $15,000 in shares of Amcor NYSE: AMCR on 8/10/2026.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $270.81 on Tuesday. The stock has a market cap of $651.93 billion, a price-to-earnings ratio of 25.45, a PEG ratio of 2.68 and a beta of 0.21. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The company's 50-day moving average price is $265.74 and its 200 day moving average price is $247.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio is 81.21%.

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the second quarter valued at $28,000. Matrix Trust Co increased its position in Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after purchasing an additional 54 shares in the last quarter. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson during the 2nd quarter worth about $43,000. Hanseatic Management Services Inc. acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $52,000. Finally, Polaris Financial Partners acquired a new position in Johnson & Johnson in the 3rd quarter valued at about $56,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the completion of the sale, the executive vice president owned 16,994 shares in the company, valued at $4,367,458. This represents a 48.37% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 64,515 shares of company stock worth $17,271,766. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of recent research reports. Stifel Nicolaus set a $260.00 target price on shares of Johnson & Johnson in a report on Wednesday, July 15th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a report on Monday, August 3rd. TD Cowen reaffirmed a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Citigroup lifted their target price on Johnson & Johnson from $298.00 to $303.00 and gave the company a "buy" rating in a research report on Monday, October 5th. Finally, Johnson Rice downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $275.92.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey's 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey's 7th Congressional District. He declared candidacy for the 2026 election. Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.